TY - JOUR T1 - Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease JF - medRxiv DO - 10.1101/2020.11.02.20224303 SP - 2020.11.02.20224303 AU - Manaf AlQahtani AU - Abdulkarim Abdulrahman AU - Abdulrahman Almadani AU - Salman Yousif Alali AU - Alaa Mahmood Al Zamrooni AU - Amal Hamza Hejab AU - Ronán M Conroy AU - Pearl Wasif AU - Stephen L Atkin AU - Sameer Otoom AU - Manal Abduljalil Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20224303.abstract N2 - Background Convalescent plasma (CP) therapy in COVID-19 disease has been suggested to improve clinical outcome in severe disease. This pilot study was designed to inform the design of a definitive phase 3 clinical trial.Methods This was a prospective, interventional and randomized open label pilot trial involving 40 patients with COVID-19 who were requiring oxygen therapy and who had radiological evidence of pneumonia. Twenty COVID-19 patients received two 200ml transfusions of convalescent patient CP over 24 hours were compared with 20 patients who received routine care alone. The primary outcome was the requirement for ventilation. The secondary outcomes were white blood cell count, lactate dehydrogenase (LDH), C-reactive protein (CRP), Troponin, Ferritin, D-Dimer, procalcitonin, mortality rate at 28 days.Results The CP group were a higher risk group with higher ferritin levels (p<0.05) though respiratory indices did not differ. The primary outcome measure – ventilation – was required in 6 controls and 4 patients on CP (risk ratio 0.67 95% CI 0.22 – 2.0, p=0.72); mean time on ventilation was 10.5 days in the control against 8.2 days in patients on CP (p=0.81). There were no differences in secondary measures at the end of the study. Two patients died in the control and one patient in the CP arm.Conclusion There were no significant differences in the primary or secondary outcome measures between CP and standard therapy though fewer patients required ventilation and for a shorter period of time. The study showed that CP therapy appears to be safe and it is feasible to perform a definitive phase 3 clinical trial using this study protocol.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04356534Funding StatementThis work was supported by the Ministry of Health Bahrain and the College of Surgeons in Ireland-BahrainAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was conducted upon the approved protocol by the National Research and Ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request ER -